European Medicines Agency approves license extension for ustekinumab to include treatment of plaque psoriasis in children between 6 and 11 years

The new approval is based on results from the Phase III CADMUS Jr study, building on the prior Phase III CADMUS study, which found that ustekinumab improved signs and symptoms of plaque psoriasis, as well as health‑related quality of life in younger patients.

PharmaTimes